The benefits of scientific collaborations are amplified by our diversity. Limiting the exchange of ideas, practices, and data across cultures has the potential to significantly retard scientific progress and adversely affect public health. Any loss of researchers and physicians will render the United States less competitive over time, and our traditionally strong research institutions and the patients they serve will be negatively affected.
We remain deeply concerned that restricting travel will prohibit participation in scientific meetings, where cutting-edge science and treatment methods are often first introduced. These in-person meetings and other global exchanges are vitally important because they provide unparalleled opportunities for collaborations and information-sharing. Such scientific and medical meetings are absolutely essential to the conquest of cancer and blood diseases.
Much of the progress that has been achieved against cancer and blood diseases has been fueled by researchers from all corners of the world. For this progress to continue it is going to require an even greater commitment to collaborations among international organizations, governments, public and private institutions, and individuals dedicated to this cause.
Therefore, we respectfully call on the Administration to consider the negative impact of its executive order on our nation’s ability to attract the world’s best scientific and clinical talent to participate in the fight against cancer and blood diseases, irrespective of their country of origin. This includes those immigrants who are inspired by the opportunity to bring their scientific curiosity and intellect to our country.